We would love to hear your thoughts about our site and services, please take our survey here.
Rather than pee all over Brighty’s bonfire, (which is mostly quoted from press releases today, so I don’t see any problem with his post at all), I like to look at the background of the company in question - today that’s Quell TX.
It appears that they have 3x “research and preclinical development” assets.
That puts it into context.
Here’s something you might like, belhus…
Imagine that Emma Walmsley is the CEO of your major competitor. Wouldn’t you just love to sign a deal for a major product that her team ignored, right under her nose?
Imagine how spending a lot of your shareholders money would feel doing that!
Ah, now you mean “ICR” don’t you?
That makes it more interesting when you take into account the tweet that Krone shared earlier.
I’m thinking photoshoot - what better than the owners and licensees signing, flanked by the other major stakeholders (SAR) ?
The thing to bear in mind for 737 is the RACI matrix:
Responsible = CPF
Accountable = CPF
Consulted = maybe SAR
Informed = SAR
Well, back in Jan 2022 RMM’s valuation of getting 1801 into clinic was an increment of 5p in old money, so £2.50 post consolidation. Add that to Friday’s closing SP gives us about £3.80 equating to a market cap of £258M
And…. both the bid and offer prices ticked up just before close to give us a closing mid point of 132.5 (and a last trade being a sell at 131 if you’re a Google finance user).
Nice little finish there. Clearly the there’s some tangible excitement for next week and someone is putting a decent wad of cash on their anticipation.
Good luck all.
Also….
That large buy at 14:33 is one of those “interesting” ones….
https://www.advfn.com/Help/trade-types-1549.html#:~:text='N'%20Non%20Protected%20Portfolio&text=Normally%20a%20transaction%20of%20a,discount%20to%20the%20market%20price.
https://uk.advfn.com/Help/trade-types-1549.html#:~:text=A%20protected%20transaction%20occurs%20when,the%20price%20of%20the%20stock.